You are here

Mark E. Robson, MD, FASCO

Chief, Breast Medicine Service
Professor of Medicine,
Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, New York

Current Research

Goal: To improve the accuracy of risk prediction in individuals who carry mutations in the BRCA1 and BRCA2 genes

Impact: Dr. Robson and his colleagues are conducting studies aimed at improving breast cancer risk assessment in BRCA mutation carriers. His work could help women and their doctors make more informed decisions about screening and prevention. 
What’s next: In addition to continuing their current work, his team will develop a mobile platform that allows women with genetic mutations to share information about genetic testing with their family, which they hope will encourage relatives to get screened.

Mutations in the BRCA genes (BRCA1 and BRCA2) are the most common drivers of breast cancer in families with a high incidence of the disease. However, there are other genetic variants that can be used to refine a person’s BRCA-associated risk of breast cancer. Dr. Robson is  focused on understanding the extent to which these variants influence risk so that BRCA mutation carriers can make more informed decisions about how to reduce their likelihood of developing breast cancer.

Full Research Summary

Research area: To improved genetic risk prediction models to help women with a high risk of breast cancer make more informed decisions.

Impact: Most breast cancers are not the result of inherited mutations in cancer causing genes. For families with a high incidence of breast cancer, however, a genetic component may underlie an inherited risk. The BRCA genes (BRCA1 and BRCA2) are the most common of these inherited mutations, but scientists have uncovered many more genes that may be implicated in an increased risk of breast cancer. Dr. Robson’s research focuses on understanding how genes influence breast cancer risk and developing more precise risk estimates to guide personalized screening and risk reduction strategies.

Current investigation: Dr. Robson and his team employ advanced technologies that incorporate information from genetic tests to enhance the precision of genetic risk assessment in women with mutations in a BRCA gene. This includes utilizing genomic markers to define a risk modifying panel, called polygenic risk score (PRS) to help women gain a better understanding of their breast cancer risk which can lead to more informed decisions about their care. 

What he has learned so far: Dr. Robson and his group have shown that common SNPs–small genetic changes in a gene—can define PRS that modify the breast cancer risk caused by a BRCA1 or BRCA2 mutation. Furthermore, since fewer than half of the relatives of women with a mutation undergo testing themselves, a method to extend the benefits of genetic testing to a greater number of family members will significantly affect their ability to protect their health. 

What’s next: Dr. Robson’s group will continue their studies to validate a risk prediction score that refines the assessment of BRCA-associated risk of breast cancer. They continue to enroll volunteers into the Prospective Registry of Multiplex Testing (PROMPT), an important resource for understanding how genes influence risk. In addition, they will develop a new mobile-enabled platform that family members of women with mutations can use to inform and educate themselves about the risks and benefits of genetic testing.


Mark Robson, MD, is an Associate Attending Physician of the Clinical Genetics and Breast Medicine Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center. He received his B.Sc. from Washington and Lee University and his MD from the University of Virginia. He performed residency and fellowship training at Walter Reed Army Medical center before coming to Memorial Sloan Kettering in 1996. He is currently the Clinic Director of the Clinical Genetics Service and the chair of the Cancer Genetics Subcommittee of the American Society of Clinical Oncology.

Dr. Robson's research is directed toward the improving the integration of genetic information into the clinical management of women with breast cancer. He and his colleagues have conducted a number of studies examining outcomes in women with hereditary breast cancer to better define the risks and benefits of treatments such as breast conserving therapy and adjuvant chemotherapy in this group. He and his coworkers have also conducted a number of studies examining the effectiveness of screening interventions such as breast MRI or ovarian cancer screening in women at hereditary risk. He is currently conducting studies to evaluate the impact of intensive screening or surgical prevention upon women's quality of life, and to develop new screening tools, such as serum peptide profiling.

Large Researcher Headshot - Robson Mark

BCRF Investigator Since


Donor Recognition

The Blizzard Entertainment Precision Prevention Award